1. Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 2014;10:592-602.
[CROSSREF] [PUBMED] [PDF]
2. de Meester I, Lambeir AM, Proost P, Scharpe S. Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol 2003;524:3-17.
[CROSSREF] [PUBMED]
3. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-294.
[CROSSREF] [PUBMED]
4. Polgar L, Szabo E. Prolyl endopeptidase and dipeptidyl peptidase IV are distantly related members of the same family of serine proteases. Biol Chem Hoppe Seyler 1992;373:361-366.
[CROSSREF] [PUBMED] [PDF]
5. Pala L, Rotella CM. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence. J Diabetes Res 2013;2013:590456
[CROSSREF] [PUBMED] [PMC] [PDF]
6. Dicembrini I, Mannucci E, Rotella CM. Bone: incretin hormones perceiver or receiver? Exp Diabetes Res 2012;2012:519784
[CROSSREF] [PUBMED] [PMC] [PDF]
7. Glorie L, Behets GJ, Baerts L, De Meester I, D'Haese PC, Verhulst A. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol Endocrinol Metab 2014;307:E447-E455.
[CROSSREF] [PUBMED]
8. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011;34:2474-2476.
[CROSSREF] [PUBMED] [PMC]
9. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009;45:833-842.
[CROSSREF]
10. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000;267:5608-5613.
[CROSSREF] [PUBMED]
11. Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:2553-2561.
[CROSSREF] [PUBMED] [PDF]
12. Iwaki-Egawa S, Watanabe Y, Kikuya Y, Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem 1998;124:428-433.
[CROSSREF] [PUBMED] [PDF]
13. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009;58:1723-1747.
[CROSSREF] [PUBMED] [PDF]
14. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917-1925.
[CROSSREF] [PUBMED] [PMC]
15. Cho EH, Cho KH, Lee HA, Kim SW. High serum osteopontin levels are associated with low bone mineral density in postmenopausal women. J Korean Med Sci 2013;28:1496-1499.
[CROSSREF] [PUBMED] [PMC]
16. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-1343.
[CROSSREF] [PUBMED]
17. Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994;40:331-338.
[CROSSREF] [PUBMED] [PDF]
18. Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys 2010;503:11-19.
[CROSSREF]
19. Driessen JH, van Onzenoort HA, Henry RM, Lalmohamed A, van den Bergh JP, Neef C, et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone 2014;68:124-130.
[CROSSREF] [PUBMED]
20. Gallagher EJ, Sun H, Kornhauser C, Tobin-Hess A, Epstein S, Yakar S, et al. The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev 2014;30:191-200.
[CROSSREF] [PUBMED] [PMC]
21. Huber BC, Brunner S, Segeth A, Nathan P, Fischer R, Zaruba MM, et al. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. Cardiovasc Res 2011;90:529-537.
[CROSSREF] [PUBMED] [PDF]
22. Grabmaier U, Brandl L, Kreiner J, Negele T, Huber BC, Rimmbach C, et al. Increased numbers of bone marrow-derived cells in parathyroid adenoma. Eur J Clin Invest 2014;44:833-839.
[CROSSREF]
23. Nishida H, Suzuki H, Madokoro H, Hayashi M, Morimoto C, Sakamoto M, et al. Blockade of CD26 signaling inhibits human osteoclast development. J Bone Miner Res 2014;29:2439-2455.
[CROSSREF] [PUBMED]
24. Zheng T, Yang L, Liu Y, Liu H, Yu J, Zhang X, et al. Plasma DPP4 activities are associated with osteoporosis in postmenopausal women with normal glucose tolerance. J Clin Endocrinol Metab 2015;100:3862-3870.
[CROSSREF] [PUBMED]
25. Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011;152:457-467.
[CROSSREF] [PUBMED] [PDF]
26. Bunck MC, Poelma M, Eekhoff EM, Schweizer A, Heine RJ, Nijpels G, et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 2012;4:181-185.
[CROSSREF] [PUBMED]